NDAORALTABLETPriority Review
Approved
Apr 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
BENEMID (probenecid) by Merck & Co. is etzadroxil, a penem antibacterial drug [see microbiology ] and probenecid, a renal tubular transport inhibitor. First approved in 1951.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Benemid (probenecid) is an oral small-molecule renal tubular transport inhibitor approved in 1951 that works by blocking OAT3-mediated renal clearance to increase plasma concentrations of certain antibacterial agents. It is used as an adjunctive therapy to enhance the efficacy and exposure of penem antibiotics like sulopenem. Probenecid inhibits renal excretion, allowing co-administered drugs to achieve higher therapeutic concentrations.
LOE Approaching
Product is in late-stage exclusivity with moderate competitive pressure (30); team focus likely shifting to LOE mitigation and lifecycle extension strategies rather than growth initiatives.
Mechanism of Action
etzadroxil, a penem antibacterial drug [see Microbiology ] and probenecid, a renal tubular transport inhibitor. Probenecid inhibits OAT3-mediated renal clearance of sulopenem, resulting in increased plasma concentrations of sulopenem .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents
Started Apr 2026
12 enrolled
Pharmacokinetics After Oral Intake
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
Started Sep 2025
25 enrolled
Healthy Adults
A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood
Started Nov 2024
15 enrolled
Healthy
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
Started Jun 2024
71 enrolled
Healthy Participants
Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
Started Sep 2022
36 enrolled
Autosomal Dominant Polycystic Kidney DiseaseNephrogenic Diabetes InsipidusAcquired Nephrogenic Diabetes Insipidus+1 more
Worked on BENEMID at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.